Zhiwei S. Zheng
Shantou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Camrelizumab plus CAPOX versus CAPOX for HER2-negative gastric or gastro-oesophageal junction adenocarcinoma: a cost-effectiveness analysis.
Journal: Frontiers in pharmacology
Published: April 13, 2026
Cost-effectiveness analysis of toripalimab and bevacizumab versus sorafenib for advanced hepatocellular carcinoma in China.
Journal: Scientific reports
Published: January 06, 2026
Platinum accumulation in chemotherapy: toxicity mechanisms, challenges, and mitigation strategies.
Journal: Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine
Published: December 05, 2025
Service delivery costs of vaccination at health facilities in Guangzhou, China.
Journal: Human vaccines & immunotherapeutics
Published: August 18, 2025
Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer.
Journal: Frontiers in public health
Published: June 10, 2025
Cadonilimab plus chemotherapy compared to chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer in China: a cost-effectiveness analysis.
Journal: BMC health services research
Published: June 03, 2025
Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis.
Journal: Frontiers in immunology
Published: March 17, 2025
Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
Journal: PloS one
Published: February 07, 2025
Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.
Journal: BMJ open
Published: December 11, 2024
Last Updated: 09/26/2026